Ardea Biosciences, Inc. clinical trials
Acquired by AstraZeneca, Jun 19, 2012 · source ↗
The registry lists 36 studies whose lead sponsor is Ardea Biosciences, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 7, 2018.
- 36studies on the registry
- 0open to participants now
Before and after it joined AstraZeneca
- First submitted before Ardea Biosciences, Inc. became part of AstraZeneca
- 9
- First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- 27
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Ardea Biosciences, Inc.’s studies test, most studies first; none is open now — 7 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 36 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed36100%
Over the years
- 08
- 09
- 10
- 11
- 12
- 1113
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Ardea Biosciences, Inc.36 studies
Something wrong with this grouping? Tell us on the AstraZeneca page.
Studies
Recruiting first, then most recently updated. Showing 36 of 36. All AstraZeneca studies →
- Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.CompletedNCT03272425Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- RDEA3170 Tablet and Capsule Bioavailability StudyCompletedNCT02448368Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Lesinurad and Febuxostat Combination Extension Study in GoutCompletedNCT01808144Phase 3
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Phase 2a RDEA3170 and Allopurinol Combination Study in Gout SubjectsCompletedNCT02498652Phase 2
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- RDEA3170 and Allopurinol Combination Study in Gout SubjectsCompletedNCT02279641Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- RDEA3170 Bioavailability StudyCompletedNCT02336594Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- RDEA3170 and Febuxostat Combination Study in Gout SubjectsCompletedNCT02246673Phase 2
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Lesinurad/Allopurinol 200/300 FDC Tablets BioequivalenceCompletedNCT02888054Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Mild, Moderate and Severe Renal Impairment StudyCompletedNCT02219516Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- DECT Study in Allopurinol-Treated Gout PatientsCompletedNCT02393560
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Lesinurad and Allopurinol Combination Extension Study in GoutCompletedNCT01808131Phase 3
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Allopurinol Combination StudyCompletedNCT01001338Phase 2
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted before Ardea Biosciences, Inc. became part of AstraZeneca
- Lesinurad/Allopurinol 200/300 FDC Tablets BioavailabilityCompletedNCT02581553Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- RDEA3170 PK/PD StudyCompletedNCT02608710Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Combining Lesinurad With Allopurinol in Inadequate RespondersCompletedNCT01510158Phase 3
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted before Ardea Biosciences, Inc. became part of AstraZeneca
- Combining Lesinurad With Allopurinol in Inadequate RespondersCompletedNCT01493531Phase 3
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted before Ardea Biosciences, Inc. became part of AstraZeneca
- Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and FebuxostatCompletedNCT01510769Phase 3
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted before Ardea Biosciences, Inc. became part of AstraZeneca
- Open-Label Lesinurad Monotherapy Extension Study in GoutCompletedNCT01650246Phase 3
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase InhibitorsCompletedNCT01508702Phase 3
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted before Ardea Biosciences, Inc. became part of AstraZeneca
- IVIVR Assessing PK Parameters Used to Establish BioequivalenceCompletedNCT02398448Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- RDEA3170 Monotherapy in Subjects With GoutCompletedNCT01927198Phase 2
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Lesinurad Tablet BioequivalenceCompletedNCT02127775Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Lesinurad Tablet Relative BioavailabilityCompletedNCT01986556Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Allopurinol Outcome StudyCompletedNCT01391325Phase 4
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted before Ardea Biosciences, Inc. became part of AstraZeneca
- Antacid Interaction StudyCompletedNCT01982201Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Bioavailability of Lesinurad and Intravenous [14C]LesinuradCompletedNCT02039700Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Gout Dose Response StudyCompletedNCT00955981Phase 2
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted before Ardea Biosciences, Inc. became part of AstraZeneca
- Metformin and Furosemide Drug-Drug Interaction StudyCompletedNCT02028689Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic GoutCompletedNCT00741442Phase 2
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted before Ardea Biosciences, Inc. became part of AstraZeneca
- Naïve HIV POC Monotherapy TrialCompletedNCT00617526Phase 2
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted before Ardea Biosciences, Inc. became part of AstraZeneca
- RDEA3170 and Febuxostat Drug Interaction StudyCompletedNCT01883167Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Lesinurad Interaction Study With RanitidineCompletedNCT01908257Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Single and Multiple Dose Study in Japanese SubjectsCompletedNCT01872832Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- RDEA3170 AME StudyCompletedNCT01910506Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- NSAID Drug Interaction StudyCompletedNCT01884272Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca
- Single and Multiple Dose Study in JapaneseCompletedNCT01744379Phase 1
Sponsor listed in the registry: Ardea Biosciences, Inc. · First submitted after Ardea Biosciences, Inc. became part of AstraZeneca